Molecular Instruments specializes in advanced technologies for RNA imaging and analysis, primarily through their proprietary HCR™ (Hybridization Chain Reaction) platform. This innovative approach enables multiplexed, quantitative, and high-resolution RNA fluorescence in situ hybridization (RNA-FISH), allowing researchers to visualize multiple RNA targets simultaneously with enhanced sensitivity and specificity. The HCR™ technology features enzyme-free signal amplification, which simplifies the protocol and minimizes background noise, ensuring that even non-specific binding does not interfere with the results. This versatility extends to various sample types, including formalin-fixed paraffin-embedded (FFPE) tissues, fresh or frozen samples, and even complex environmental samples.

In addition to RNA-FISH, Molecular Instruments offers complementary technologies such as HCR™ protein immunofluorescence (IF) and quantitative RNA flow cytometry. These methods leverage the same probe sets and amplification strategies, facilitating simultaneous imaging of RNA and protein targets. The HCR™ platform supports multiple quantitative analysis modes, including subcellular and single-molecule RNA imaging, as well as quantitative northern blotting. This comprehensive suite of tools is designed to enhance research capabilities across a wide range of biological applications, providing researchers with robust, reliable, and user-friendly solutions for RNA analysis.

United States

Molecular Instruments®(MI) designs and synthesizes kits for multiplexed, quantitative, high-resolution bioimaging in academic research, drug development, and clinical pathology and diagnostics. Their HCR™technology introduced the concept of conditional nucleic acid self-assembly — a foundational principle for the field of dynamic nucleic acid nanotechnology.

Molecular Instruments

Company Details